Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Cancer Research Center

www.dkfz.de

Latest From Whitby Pharmaceuticals Inc.

Patheon opens new Canadian premises

Contract development company Patheon has opened a new pharmaceutical development services suite in Whitby, Canada.

Canada

Patheon increases third-quarter revenues by 18%

The Canadian pharmaceutical development and manufacturing services firm Patheon has reported an 18% increase of revenues to $195 million in its third quarter ended July 31st, and EBITDA before repositioning expenses of $24.7 million, versus $20.6 million in the same quarter last year. It made a net loss of $14.7 million in the quarter. Commercial manufacturing revenues increased by 15% to reach $157.3 million, driven by strong growth in its European business, while pharmaceutical development services revenues increased by 32% to $37.7 million. Patheon has focused on improving its underlying profitability with a restructuring programme and reducing its headcount, while also investing in staff training and development programmes. It is consolidating its York Mills and Whitby operations in Canada, and its Puerto Rico facilities.

Puerto Rico Companies

Dealmaking Trends, Part II: The Valuation Divide

Late-stage products are more valuable than ever, as products and as licensing currency. Drug originators, for example, can generate the same kinds of partner funding and commitment from mere co-promotions that were once available only from joint ventures or outright exclusive out-licensing deals. But no one except Big Pharma seems to reap the rewards on Wall Street--largely because investors believe that new entrants can't overcome the increasing barriers to the drug business. With their shares in the doghouse, biotechs who have successfully launched products are struggling to craft strategies that will prove their staying power and long-term value.
BioPharmaceutical Strategy
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register